Telotristat etiprate

Telotristat Etiprate (pronounced as te-lo-tri-stat e-tip-rate) is a medication used in the treatment of Carcinoid Syndrome related diarrhea. It is marketed under the brand name Xermelo.

Etymology

The name Telotristat Etiprate is derived from the chemical structure of the drug. 'Telotristat' refers to the active ingredient, and 'Etiprate' refers to the salt form of the drug.

Pharmacology

Telotristat Etiprate is a tryptophan hydroxylase inhibitor. It works by reducing the production of serotonin in the body, which is overproduced in people with Carcinoid Syndrome. This overproduction can lead to severe diarrhea and other symptoms.

Usage

Telotristat Etiprate is used in combination with somatostatin analog therapy for the treatment of Carcinoid Syndrome diarrhea in adults inadequately controlled by somatostatin analog therapy.

Side Effects

Common side effects of Telotristat Etiprate include nausea, headache, elevated liver enzymes, depression, peripheral edema, flatulence, decreased appetite, and fever.

Related Terms

• Carcinoid Syndrome
• Serotonin
• Somatostatin analog
• Tryptophan hydroxylase inhibitor

External links

• Medical encyclopedia article on Telotristat etiprate
• Wikipedia's article - Telotristat etiprate

This WikiMD dictionary article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski